Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

To study the profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease

Phase 1

Luye Pharma Group Ltd.

N 0437
Rotigotine